NCT07061145View on ClinicalTrials.gov

A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia

RecruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2028

Conditions
Chronic Myelocytic LeukemiaErectile DysfunctionsCVD - Cardiovascular DiseaseTyrosine Kinase Inhibitor
Interventions
DRUG

Tirosin Kinase Inhibitors

Tyrosine kinase inhibitor (TKI) administered as part of standard clinical care for CML. No experimental treatment is applied. Exposure to the drug will be analyzed in association with erectile dysfunction outcomes.

Trial Locations (1)

42121

RECRUITING

Azienda USL IRCCS di Reggio Emilia, Reggio Emilia

All Listed Sponsors
lead

Azienda USL Reggio Emilia - IRCCS

OTHER_GOV